Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

BACKGROUND: In patients with ulcerative colitis (UC), risks of infection and malignancies increase with age. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. This analysis assessed age as a risk factor for adverse events of special interest (AESI) in the tofacit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lichtenstein, Gary R, Bressler, Brian, Francisconi, Carlos, Vermeire, Severine, Lawendy, Nervin, Salese, Leonardo, Sawyerr, Gosford, Shi, Hongjiong, Su, Chinyu, Judd, Donna T, Jones, Thomas, Loftus, Edward V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825287/
https://www.ncbi.nlm.nih.gov/pubmed/36342120
http://dx.doi.org/10.1093/ibd/izac084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825287/
https://www.ncbi.nlm.nih.gov/pubmed/36342120
http://dx.doi.org/10.1093/ibd/izac084

Ejemplares similares